Salinas Pablo, Moreno Raúl, Calvo Luis, Jiménez-Valero Santiago, Galeote Guillermo, Sánchez-Recalde Angel, López-Fernández Teresa, Garcia-Blas Sergio, Iglesias Diego, Riera Luis, Moreno-Gómez Isidro, Mesa Jose María, Plaza Ignacio, Ayala Rocio, Gonzalez Rosa, López-Sendón José-Luis
Pablo Salinas, Raúl Moreno, Luis Calvo, Santiago Jiménez-Valero, Guillermo Galeote, Angel Sánchez-Recalde, Division of Interventional Cardiology, University Hospital La Paz, 28046 Madrid, Spain.
World J Cardiol. 2012 Jan 26;4(1):8-14. doi: 10.4330/wjc.v4.i1.8.
To study a cohort of consecutive patients undergoing transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR).
All consecutive patients undergoing TAVI in our hospital were included. The AF group comprised patients in AF at the time of TAVI or with history of AF, and were compared with the SR group. Procedural, echocardiographic and follow-up variables were compared. Likewise, the CHA(2)DS(2)-VASC stroke risk score and HAS-BLED bleeding risk score and antithrombotic treatment at discharge in AF patients were compared with that in SR patients.
From a total of 34 patients undergoing TAVI, 17 (50%) were allocated to the AF group, of whom 15 (88%) were under chronic oral anticoagulation. Patients in the AF group were similar to those in the SR group except for a trend (P = 0.07) for a higher logistic EuroSCORE (28% vs 19%), and a higher prevalence of hypertension (82% vs 53%) and chronic renal failure (17% vs 0%). Risk of both stroke and bleeding was high in the AF group (mean CHA(2)DS(2)-VASC 4.3, mean HAS-BLED 2.9). In the AF group, treatment at discharge included chronic oral anticoagulation in all except one case, and in association with an antiplatelet drug in 57% of patients. During a mean follow-up of 11 mo (maximum 32), there were only two strokes, none of them during the peri-procedural period: one in the AF group at 30 mo and one in the SR group at 3 mo. There were no statistical differences in procedural success, and clinical outcome (survival at 1 year 81% vs 74% in AF and SR groups, respectively, P = NS).
Patients in AF undergoing TAVI show a trend to a higher surgical risk. However, in our cohort, patients in AF did not have a higher stroke rate compared to the SR group, and the prognosis was similar in both groups.
研究一组接受经导管主动脉瓣植入术(TAVI)的连续患者,并比较心房颤动(AF)患者与窦性心律(SR)患者的结局。
纳入我院所有接受TAVI的连续患者。AF组包括TAVI时处于AF状态或有AF病史的患者,并与SR组进行比较。比较手术、超声心动图和随访变量。同样,比较AF患者与SR患者的CHA(2)DS(2)-VASC卒中风险评分、HAS-BLED出血风险评分及出院时的抗栓治疗情况。
在总共34例接受TAVI的患者中,17例(50%)被分配到AF组,其中15例(88%)接受慢性口服抗凝治疗。AF组患者与SR组患者相似,但AF组的逻辑欧洲心脏手术风险评估系统(EuroSCORE)有更高的趋势(P = 0.07)(28%对19%),高血压患病率更高(82%对53%),慢性肾衰竭患病率更高(17%对0%)。AF组的卒中和出血风险均较高(平均CHA(2)DS(2)-VASC为4.3,平均HAS-BLED为2.9)。在AF组,除1例患者外,出院时的治疗包括所有患者的慢性口服抗凝治疗,57%的患者联合使用抗血小板药物。在平均11个月(最长32个月)的随访期间,仅发生2次卒中,均不在围手术期:1次发生在AF组30个月时;1次发生在SR组3个月时。手术成功率及临床结局无统计学差异(AF组和SR组1年生存率分别为81%和74%,P = 无显著性差异)。
接受TAVI的AF患者手术风险有升高趋势。然而,在我们的队列中,AF患者与SR组相比卒中发生率并未更高,两组预后相似。